HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by El-Gamel, A. Articles by Hutchinson, I. V. Search for Related Content PubMed PubMed Citation Articles by El-Gamel, A. Articles by Hutchinson, I. V.

Eur J Cardiothorac Surg 1998;13:424-430
© 1998 Elsevier Science NL

Transforming growth factor-ß₁ and lung allograft fibrosis¹

^a Cardiothoracic Transplant Unit, Wythenshawe Hospital, Manchester M23 9LT, UK
^b North West Lung Centre, Wythenshawe Hospital, Manchester, UK
^c Tissue Typing Laboratory, Central Manchester Health Trust, Manchester, UK
^d School of Biological Sciences, Manchester University, Manchester, UK

Received 30 September 1997; received in revised form 29 December 1997; accepted 10 February 1998.

Corresponding author. Tel.: +44 161 9987070; fax: +44 161 9212091; e-mail: aelgamel@ aol.com

Objectives: Transforming growth factor ß₁ (TGF-ß₁) is a potent immunosuppressive cytokine that promotes fibrosis by enhancing the synthesis of extracellular matrix components. The repair process following lung allograft injury is due to rejection or infection replaces lung parenchyma by fibrotic tissue, leading to pulmonary dysfunction. The role of TGF-ß₁ in this excessive healing process and increasing the risk of infection is unknown. Methods: We analysed our patient data to investigate the relevance of different factors on allograft fibrosis and its correlation with TGF-ß₁. Fibrosis was graded in H and E stained sections. TGF-ß1 genotype was determined in all patients. Results: Patients were aged between 16 and 62 years (mean age of 39.6 years). Procedures were heart/lung (n=32), double lung (n=18), and SLT (n=41). A total of 46 patients had lung allograft fibrosis diagnosed in transbronchial biopsies sections. Patients who had developed interstitial fibrosis had significantly more acute rejection episodes (mean 3.4±2.8) compared with patients without fibrosis (mean 2.1±2.2) (P=0.024). The presence of eosinophils in the interstitium preceded and were associated with the development of fibrosis regardless of the rejection grade (P=0.0001). TGF-ß₁ was heavily expressed in sections with fibrosis with a mean score of 6.8±2.9 compared with 2.4±0.6 in sections with no fibrosis (P<0.0001). TGF-ß₁ expression correlated positively with fibrosis grades (P<0.0001). The mean survival for patients with a fibrosis score >6 is 892.4±73 days compared with mean survival 427±78 in patients with scores <6 (P=0.0001). Patients who developed fibrosis had homozygous TGF-ß₁ genotype that correlates with excessive TGF-ß₁ expression (P=0.01). The use of cardiopulmonary bypass was associated with the development of excessive fibrosis (P=0.02), and 7 patients who had severe fibrosis died of septicaemia (17.5%). FEV1 (forced expiratory volume) was significantly higher in patients without fibrosis (1870±111 ml versus 1590±160; P=0.02). Conclusions: The risks of lung allograft fibrosis increases with recurrent rejection, tissue eosinophilia, homozygous TGF-ß₁ genotype and the use of bypass machine. Fibrosis was associated with higher mortality and morbidity might be explained by the TGF-ß₁ immunosuppressive and fibrotic properties. Immunological strategies to down-regulate TGF-ß₁ production might improve survival and function of lung allografts.

Key Words: Transforming growth factor-ß₁ • Lung transplantation • Allograft

This article has been cited by other articles:

				M. LIU, M. SUGA, A. A. MACLEAN, J. A. ST. GEORGE, D. W. SOUZA, and S. KESHAVJEE Soluble Transforming Growth Factor-beta Type III Receptor Gene Transfection Inhibits Fibrous Airway Obliteration in a Rat Model of Bronchiolitis Obliterans Am. J. Respir. Crit. Care Med., February 1, 2002; 165(3): 419 - 423. [Abstract] [Full Text] [PDF]

				J. M. Mason, H.-P. Xu, S. K. Rao, A. Leask, M. Barcia, J. Shan, R. Stephenson, and S. Tabibzadeh Lefty Contributes to the Remodeling of Extracellular Matrix by Inhibition of Connective Tissue Growth Factor and Collagen mRNA Expression and Increased Proteolytic Activity in a Fibrosarcoma Model J. Biol. Chem., January 4, 2002; 277(1): 407 - 415. [Abstract] [Full Text]

				R K Coker, G J Laurent, P K Jeffery, R M du Bois, C M Black, and R J McAnulty Localisation of transforming growth factor {beta}1 and {beta}3 mRNA transcripts in normal and fibrotic human lung Thorax, July 1, 2001; 56(7): 549 - 556. [Abstract] [Full Text] [PDF]

				A. A. MACLEAN, M. LIU, S. FISCHER, M. SUGA, and S. KESHAVJEE Targeting the Angiotensin System in Posttransplant Airway Obliteration . The Antifibrotic Effect of Angiotensin Converting Enzyme Inhibition Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 310 - 315. [Abstract] [Full Text]

				P. D Arkwright, S. Laurie, M. Super, V. Pravica, M. J Schwarz, A K. Webb, and I. V Hutchinson TGF-beta 1 genotype and accelerated decline in lung function of patients with cystic fibrosis Thorax, June 1, 2000; 55(6): 459 - 462. [Abstract] [Full Text]